<DOC>
	<DOCNO>NCT01549301</DOCNO>
	<brief_summary>The primary aim study compare pharmacokinetic pharmacodynamic effect two commercial preparation filgrastim ( T C ) , single dose via subcutaneous intravenous administration concentration 5 mcg/kg 10 mcg/kg healthy subject alteration pharmacokinetic pharmacodynamic parameter ( measurement serum level G-CSF absolute neutrophil count - ANC ) .</brief_summary>
	<brief_title>Evaluation Pharmacokinetic Pharmacodynamic Parameters Filgrastim ( G-CSF ) Produced Blausiegel Indústria e Comércio Ltda . Compared Granulokine Produced Produtos Roche Químicos e Farmacêuticos S/A .</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Agree study procedure , sign date back free , IC ; Be 18 50 year , sex ; Present body mass index ( BMI ) great equal 20 less equal 28 ; consider healthy , clinical , psychological laboratory ; female , maintain safe method contraception study . Known hypersensitivity filgrastim ; Hypersensitivity product derive E. coli ; fever infectious disease 07 day precede first administration ; Positive serology hepatitis B C HIV ; Prior treatment CSFs , interleukins interferon ; Participation clinical study last 12 month ; Donation loss blood 03 month precede study ; General anesthesia 03 month precede study ; Provide history alcohol abuse , drug drug ; Have history liver disease , renal , pulmonary , gastrointestinal , hematological , psoriasis , gout , acute myocardial infarction , thyroid psychiatric disease ; Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>